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Abstract This study examined the effect of cannabinoid ligands 
on human tonsillar B-cells activated either through cross-linking 
of surface immunoglobulins or ligation of the CD40 antigen. The 
two synthetic annabinoids, CP55,940 and WIN55212-2, as well 
as Ag-tetrahydrocannabinol (THC), the psychoactive component 
of marijuana, caused a dose-dependent i crease of B-cell prolifer- 
ation and displayed ECso at low nanomolar concentrations. This 
cannabinoid-induced nhancing activity was inhibited by pertussis 
toxin which suggested a G-protein-coupled receptor process. In 
addition, the absence of antagonistic effect of SR141716A, a 
specific CB1 receptor antagonist, together with the demonstra- 
tion that human B-cells displayed large amount of CB2 receptor 
mRNAs, led us to assume that the growth enhancing activity 
observed on B-cells at very low concentrations of cannabinoids 
could be mediated through the CB2 receptor. 
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1. Introduction 
In addition to psychotropic effects, many reports have de- 
scribed an influence of cannabinoids on immune function (re- 
view, see [1]). Most of the in vitro studies showed immunosup- 
pressive effects of cannabinoids (CB): inhibition of mitogen- 
induced proliferative responses of T-lymphocytes and B-lym- 
phocytes [2,3], of cytotoxic T-cell activity [4], of macrophage 
microbiocidal activity and TNFcz synthesis [5,6], of cytolytic 
activity and TNFc~ production of large granular lymphocytes 
[7]. In some studies, enhancing effects were observed: increase 
of interleukin-1 bioactivity by mouse resident macrophages or 
human differentiated macrophagic ell lines due to increased 
levels of TNF~z [8,9]. 
Kaminsky et al. [10] identified the presence of CB receptors 
on mouse spleen cells. Bouaboula et al. [11] demonstrated that 
the first type cannabinoid receptor (CB1) which is present in 
the brain is also expressed on human leukocytes and Munro et 
al. [12] cloned a second G-protein coupled cannabinoid recep- 
tor, designated CB2, that is only present at the periphery and 
more particularly on cells of immune origin. More recently, 
Galiegue et al. [13] demonstrated that CB2 receptors mRNAs 
are highly expressed in human tonsils and B-cells. Thus, the 
presence of CB receptors on lymphoid cells could account for 
the cannabinoid-mediated immune modulation reported above. 
However, in most cases, the effects were obtained at concentra- 
tions of cannabinoids much higher (> 1/IM) than those required 
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in binding experiments (nanomolar affinities) (M. Rinaldi-Car- 
mona, submitted), raising the question of receptor-mediated 
versus non-receptor-mediated mechanisms. 
In contrast with the studies which report immunosuppressive 
effects at physiologically irrelevant concentrations of cannabi- 
holds, we show here that various cannabinoid ligands displayed 
a growth enhancing activity on human tonsillar B-cells at a 
nanomolar ange of concentrations. This activity was shown to 
be inhibited by pertussis toxin (PTX), strongly suggesting a
specific receptor-mediated mechanism. Further, the presence in 
these cells of large amounts of CB2 receptor mRNAs and the 
absence of antagonistic effect of SR141716A, a recently de- 
scribed selective antagonist of the CB1 receptor [14], seemed to 
indicate a CB2 receptor-mediated process. 
2. Materials and methods 
2. l. Materh~ls 
CP55,940 was generously provided by Pfizer. WIN55212-2 was pur- 
chased from RBI (Natick, USA), Ag-THC and pertussis toxin were 
obtained from Sigma (St. Quentin- Fallavier, France). SR 141716A and 
Anandamide ~ere synthesised at Sanofi Recherche. Drugs were dis- 
solved in dimethyl sulfoxide at 10 ~ M. The tinal concentration of 
solvent in assays never exceeded 0.01% and was without effect on 
experiments. The 3All and F111-409 monoclonal antibodies (mAb 
ami-CD2 and anti-CD3, respectively) used for depletion ofT-cells from 
tonsils were produced at Sanofi Recherche. The polyclonal B-cell acti- 
vator, rabbit anti-human surface immunoglobulins (anti-lgs) antibody 
coupled to polyacrylamide b ads were purchased from Bio-Rad Labo- 
ratories (Richmond, USA). The anti-CD40 mAb, MAB89. was pur- 
chased from Immunotech S.A. (Marseille, France). The mouse fibro- 
blast L cells stably transfected with human Fc?'RJI/CDw32 (CDw32 k 
cells) were obtained from the American Type Culture Collection (Rock- 
ville, USA) with the agreement ofDr. J. Banchereau (Schering-Plough, 
Dardilly, France). 
2.2. Human B-cell pur(fication 
B-Cells were isolated as previously described [15]. Briefly, cells from 
tonsil specimens were incubated with mAbs directed at T-cells (anti- 
CD2 and anti-CD3) at 2/ag per 106 estimated target cells, for 30 min 
at 4°C, washed and then incubated 30 min at 4°C wilh sheep anti- 
mouse IgG-conjugated magnetic beads (Dynabeads, Dynal, Oslo, Nor- 
way) at a bead-to-target cell ratio of 5 : 1. Negative selection of B-cells 
was performed by magnetic depletion of bead-bound T-cells and re- 
sulted in > 95% pure B-cells as determined by FACS analysis (Becton 
Dickinson and Co.) using anti-CD20, -CD4, -CD8 and -CDI4 mAbs. 
2.3. Detection ~ CBI and CB2 receptor mRNAs 
The expression ofmRNAs for fl2-microglobulin, CB 1 and CB2 recep- 
tors were examined by reverse transcription coupled to the polymerase 
chain reaction (RT-PCR) in the exponential phase of amplification as 
previously described [11]. Briefly, the total human tonsillar B-cell RNA 
was extracted using guanidinium isothiocyanate, purified by CsCI gra- 
dient ultracentrifugation a d reverse transcribed to the corresponding 
cDNA [1 I]. Human brain cortex cDNA was purchased from Clontech 
(Palo Alto, USA). DNA amplifications were carried out in PCR buffer 
supplemented with 1.5 mM MgCI 2 containing 1ng ofcDNA with 0.1 
mM dNTP, 0.25 /aM of each primer, (1.5 tJ /hq polymerase (Perkin 
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Elmer-Cetus) in a final volume of 20/.tl. The mixture was amplified with 
the GeneAmp PCR System 9600 thermal cycler (Perkin Elmer-Cetus). 
The thermal reaction profile consisted of a denaturation step at 95°C 
for 20 s, annealing at 60°C for 30 s and an extension step at 75°C for 
20 s. Reaction was performed for 30 cycles. After PCR, 5/A loading 
buffer (Novex, San Diego, USA) were mixed with 10/A PCR products 
and separated by electrophoresis on 3% agarose gel in the presence of 
ethidium bromide with 123 bp DNA markers (Gibco, Eragny, France) 
as molecular weight controls. 
All the primers were 20-residue oligonucleotides with 50% G+C 
content and lacking 3' complementary between primer pairs./32-Mi- 
croglobulin primers: sense 5'-CCAGCAGAGAATGGAAAGTC-3'; 
antisense 5'-GATGCTGCTTACATGTCTCG-3'. CB1 primers: sense 
5'-CATCATCATCCACACGTCTG-3'; antisense 5'-ATGCTGTTA- 
TCCAGAGGCTG-3'. CB2 primers: sense 5'-TTTCCCACTATCCC- 
CAATG-3'; antisense 5'-AGTTGATGAGGCACAGCATG-3'. 
2.4. Anti-Igs assay 
Apart from experiment depicted in Fig. 1, all cultures were performed 
in RPMI 1640 supplemented with 0.5% heat-inactivated f tal calf serum 
(FCS), 2 mM L-glutamine, 100 U/ml penicillin, 100/zg/ml streptomycin 
and 5 mM HEPES buffer (thereafter named: RPMI-0.5). B-cells were 
seeded at 1.5 × 105 cells/well of 96-well microplates in a final volume of 
0.2 ml. Unless otherwise stated, the anti-Igs polyclonal B-cell activator, 
used at a final dilution of 1/10000, and the cannabinoid ligands were 
added at the onset of the culture. Each culture point was performed in 
12 replicates. At the times specified in the text, DNA synthesis was 
determined by pulsing the cells with 1 ~uCi/well of [3H]thymidine for the 
last 16 h of the culture period. 
2.5. Anti-CD40/CDw32 L cell assay 
We employed a modified version of the B-cell in vitro culture system 
described by Banchereau et al. [16] where mAbs to CD40 antigen are 
presented in a cross-linked fashion by CDw32 transfected mouse L 
cells. CDw32 L cells suspended at 2 × 106/ml were treated with 100 
~tg/ml mitomycin C in RPMI-0.5 for 1 h at 37°C. These cells were then 
washed four times in the same medium and plated at 2.5 × 104/well of 
96-well microtiter tray. They were allowed to adhere for 2 h at 37°C 
in the presence of 100 ng/ml of the anti-CD40 mAb (MAB 89). B-Cells 
at 5 × 104/well and cannabinoid ligands at the indicated concentrations 
were then added in a final volume of 0.2 ml. DNA synthesis was 
measured in 12 replicates as described above. 
A 
B 
Fig. 1. Cannabinoid-receptor gene expression in human B-cells and 
human brain cortex. PCR products were obtained after amplification 
of mRNA-derived cDNA from human tonsillar B-cells (A) and human 
brain cortex tissues (B) using CBl-and CB2-specific primers. Negative 
control was performed with no cDNA. Internal control was obtained 
by PCR of fl2-microglobulin gene. 
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Fig. 2. Influence of serum concentration cannabinoid-induced B-cell 
activation. B-cells were costimulated with anti-Igs and 10 nM CP55,940 
for 72 h in RPMI medium containing the indicated concentrations of 
FCS. Results are expressed as % increase of thymidine uptake by 
comparison with control cells stimulated by anti-Igs only and are based 
on two independent experiments. *P -< 0.05, 
2.6. Statistical analysis. 
Data were analysed by the Dunnett's analysis of variance test. A 
cut-off value of P -< 0.05 was used to indicate statistical significance 
between cannabinoid-treated c lls and control cells. Each experiment 
was repeated at least twice. 
3. Resu l ts  
3.1. Human B-cells displayed large amount of  CB2 receptor 
mRNAs  
Using semi quantitative RT-PCR, we compared in human 
brain and human B-cells the levels of trancripts for CB1 and 
CB2 receptors. As shown on Fig. 1, B-cells displayed much 
more CB2 receptor mRNAs  than CB1 receptor mRNAs.  This 
data confirmed the results obtained by Gali6gue et al. [13] who 
showed an about 10-fold higher expression of CB2 mRNAs 
than CB1 mRNAs in human tonsil lar B-cells. In the brain, no 
CB2 receptor mRNA was detected whereas CB1 receptor tran- 
scripts were highly expressed. Thus, in addit ion to the presence 
of CB1 receptor trancripts we confirmed here that human B- 
cells displayed even more CB2 receptor mRNAs.  The presence 
of both types of receptor transcripts provided a molecular basis 
for the evaluation of the potential effects of cannabinoid li- 
gands on human B-cell activation. 
3.2. Effect of  cannabinoid ligand~ on human B-cells activated by 
cross-linking of  Igs 
First, we examined the influence of the reference compound 
CP55,940 at 10 -8 M on human tonsil lar B-cells stimulated by 
cross-linking of their surface immunoglobul ins for 72h in cul- 
ture medium containing different concentrations of FCS (Fig. 
2). The results showed that at low concentrat ions of serum 
(0.25% and 0.5%), CP55,940 induced a significant 42% to 45% 
increase of thymidine uptake. This effect decreased ramati- 
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Fig. 3. Effect of different cannabinoid ligands on B-cells activated by cross-linking of lgs. B-cells were co-stimulated with anti-lgs and the indicated 
concentrations of cannabinoid ligands for 72 h in RPMI 0.5% FCS. The data shown tire representative of three separate xperiments in which each 
point (mean _+ S.D.) was measured in twelve replicates. *P -< 0.05. 
cally with the increase of serum concentration and was almost 
totally abolished at 5% of FCS. This serum inhibition was 
probably due to a loss of activity of the lipophilic cannabinoid 
ligand because of non-specific interactions with serum compo- 
nents as it has been already described elsewhere [17]. Therefore, 
all the experiments depicted thereafter were performed at the 
optimal concentration of 0.5% FCS. 
Different cannabinoid ligands were then compared (Fig. 3). 
The results showed that CP55,940, WIN55212-2 and Ag-THC 
dose-dependently increased the rate of DNA synthesis induced 
by anti-lgs. An exposure to 10 ~ to 10 .7 M led to an about 40% 
increase of thymidine uptake. The two potent synthetic can- 
nabinoids, CP55,940 and WIN55212-2, were similarly efficient 
displaying an ECs0 of 0.5 and 0.7 nM, respectively, and reached 
a plateau between 10 -8 and 10 7 M, whereas A9-THC, the psy- 
choactive component of marijuana, was slightly less active with 
an ECs~ of 2 nM. No stimulation of B-cell growth was observed 
when cannabinoids were tested in absence of costimulating 
agent (data not shown). Anandamide, the putative ndogenous 
cannabinoid ligand 18, proved to be ineffective in this model 
even at higher concentrations (->1 /IM) (data not shown) 
When the selective CB1 receptor antagonist SR141716A [14] 
was used over a wide range of concentrations together with 10 -9 
M CP55,940, no blocking effect was observed (Fig. 4). A similar 
result was obtained with A%THC and WIN55212-2 (data not 
shown) 
The kinetics of CP55,940-induced enhancement of B-cell ac- 
tivation were next evaluated by two different approaches. In the 
first set of experiments (Fig. 5A), CP55,940 at 10 nM and thc 
anti-Igs activator were added together at the onset of the cul- 
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Fig. 5. Kinetics of cannabinoid-induced growth-enhancing activity. B-Cells were stimulated with the anti-Igs activator and 10 nM CP55,940. 
(A) anti-Igs and CP were added together and [3H]thymidine uptake was measured at each indicated time. (B) cells were stimulated with anti-Igs for 
72 h and CP was sequentially added 24, 48, 72 h before [3H]thymidine labeling. Results are expressed as in Fig. 2. Two independent experiments 
showed similar results. *P -< 0.05. 
ture and % increase of DNA synthesis was measured each day 
from day 1 to day 3. In the second set of experiments (Fig. 5B), 
the activator was present over the three-day period and the 
cannabinoid was sequentially added 72, 48 and 24 h before 
[3H]thymidine labeling. Both types of experiments showed that 
the cannabinoid-induced B-cell enhancing effect was a late 
event which required at least a 48 h exposure. 
3.3. Cannabinoid-induced enhancement ofB-cell activation after 
ligation of the CD40 antigen 
The growth promoting activity described above seemed to be 
a general phenomenon which was also observed when another 
activation pathway was used. Indeed, when human B-cells were 
stimulated by engagement of the CD40 antigen by monoclonal 
antibodies presented by CDW32 L cells, a similar enhancing 
activity of CP55,940 was observed which reached 60% to 70% 
above control cells at 10-100 nM after 72 h of culture (Fig. 6A). 
This type of activation which induced a more sustained B-cell 
growth 16, allowed to observe that the cannabinoid-induced 
increase of DNA replication was permanent and within a sim- 
ilar range until 6 days after priming with anti-CD40 antibodies 
(Fig. 6B). 
3.4. Effect of pertussis toxin on cannabinoid-induced B-cell 
growth 
Cannabinoid receptors are coupled to an inhibitory subunit 
of G-protein (G~) as indicated by numerous data demonstrating 
substantial cannabinoid suppression of adenylyl cyclase activ- 
ity [19,20]. In order to confirm that the enhancing effect noticed 
in our model was a specific receptor-mediated process, we incu- 
bated B-cells in the presence of pertussis toxin (PTX) which 
blocks Gi proteins by preventing the dissociation of their c~ from 
illT/subunits [21]. Fig. 7A shows that the 38% increase of thy- 
midine uptake induced by 10 nM CP55,940 on B-cells costimu- 
lated with anti-Igs was completely abolished when cells were 
cultured with 0.1 pg/ml PTX. In contrast, when a high concen- 
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presented by CDW32-transfected L-cells. (A) Dose~effect of CP55,940 was studied over a 72 h period of culture. (B) Kinetics of cannabinoid-induced 
enhancement of B-cell activation were evaluated at 10 nM CP55,940. The results are the mean + S.D. of twelve determinations from one representative 
experiment out of three. *P -< 0.05. 
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tration of CP55,940 (10 #M) was used in the same conditions, 
a major inhibition of DNA synthesis was observed which was 
not blocked by PTX (Fig. 7B). 
4. Discussion 
To date, most studies that have examined the effects of can- 
nabinoids on immune functions have demonstrated some de- 
gree of immunosuppression after exposure to high concentra- 
tions of ligands [22-24]. In this study, we have concentrated on
exposure of human B-cells to physiologically relevant concen- 
trations of cannabinoids and in conditions of low level of 
serum, since non-specific associations of cannabinoids with 
serum lipoproteins and albumin have been demonstrated [17]. 
The dramatic loss of activity due to these interactions already 
observed in other studies, was experienced in the model pre- 
sented here where high concentrations of serum inhibited the 
cannabinoid-induced effect on B-cells. 
In optimal conditions, our study shows that nanomolar con- 
centrations of the two synthetic annabinoids, CP55,940 and 
WIN55212-2, as well as A9-THC, the psychoactive component 
of marijuana, were able to significantly increase DNA synthesis 
of human B-cells co-stimulated with either anti-Igs or anti- 
CD40 antibodies. This range of concentrations which corre- 
lated with the nanomolar affinities observed in binding studies 
on CHO cells tranfected with CB1 or CB2 receptors (M. Ri- 
naldi-Carmona, submitted) was the first indication for a recep- 
tor-mediated process. The demonstration f a plateau between 
10 and 100 nM which indicated a saturation process, repre- 
sented an additional evidence. Cannabinoid receptors are cou- 
pled to G-proteins and numerous laboratories have demon- 
strated that cannabinoids inhibit adenylyl cyclase most likely 
by interaction with G~ [20,21]. Using pertussis toxin to block G~ 
protein, we demonstrated that the stimulating effect of low 
concentrations of cannabinoid on B-cells was abolished. The 
pertussis toxin sensitivity of this phenomenon provided a third 
strong indication for a receptor-mediated mechanism. 
Anandamide, a candidate ndogenous ligand isolated from 
porcine brain [18], was evaluated over a wide range of concen- 
trations and found to be ineffective in this model. In the rat, 
it has been reported that anandamide isplayed an affinity for 
the peripheral receptor 30-fold less than that reported for the 
brain receptor [12]. The lower affinity for the CB2 receptor 
could account, at least in part. for the absence of strictly 
peripheral effect on human B-cells. In addition, some enzymatic 
breakdown leading to inactivation of anandamide could occur 
[20]. Because no steps were taken to curtail catabolism in the 
model presented here, degradation ofanandamide could not be 
totally ruled out and might represent another possibility for the 
lack of enhancing effect on B-cell growth. These different hy- 
potheses need to be explored beti~re drawing definitive conclu- 
sion. 
The stimulating effects observed here with cannabinoid li-
gands were in contrast with the inhibiting effects on lymphocyte 
proliferation reported in other studies [3,24]. However, it is 
noteworthy that inhibition was obtained at micromolar concen- 
trations (10 100 #M), raising the question of high-concentra- 
tion non-specific membrane effects probably due to lipophilic 
interactions [19]. When cannabinoid was used at the high con- 
centration of 10 #M, we also found an inhibition of B-cell 
activation which confirmed the experiments reported above by 
other laboratories. However. in this case. the pertussis toxin 
was ineffective in blocking this effect, thus reinforcing the like- 
lihood of a non-receptor-mediated process at high concentra- 
tions of cannabinoids. Nevertheless, it cannot be completely 
excluded that other receptor-coupled second messenger sys- 
tems could be involved. Watz et al. [25] also found a differential 
effect of cannabinoids on interferon- secretion by human mac- 
rophages: stimulatory effect at physiologically achievable con- 
centrations of Ag-THC (10 100 ng/ml), suppressive ffect at 
concentrations of THC above physiologically obtainable vels 
(5 20#g/ml). As in our model, this could account for receptor- 
mediated effect versus non-specific effect on the membranes of
the lymphoid cells. 
Lynn et al. [19] in an extensive study on localization of can- 
nabinoid receptors in peripheral tissues in the rat found that CB 
receptors were mainly confined to B lymphocyte-enriched areas 
and Munro el al, [12] identified in the same species the gene for 
the CB2 receptor which is expressed in splenic ells but not in 
the brain. Recently, Bouaboula et al. [11] demonstrated that, 
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among the different human leukocyte subsets tested, B-lympho- 
cytes are the cells expressing the higher level of central type 
cannabinoid receptor transcripts. In this study, we confirmed 
the results of Gali6gue et al. [13] who demonstrated that in 
addition to CBI receptor mRNAs, human B-cells express very 
high level of CB2 receptor mRNAs. With regard to CB1 versus 
CB2 receptor-mediated process, it is noteworthy that CP55,940 
and WIN55212-2 displayed a same potency on human B-cell 
activation. This result was consistent with the similar affinity 
of both ligands for the CB2 receptor whereas a 10-fold lower 
affinity of WIN55212-2 compared to that of CP55,940 was 
reported for the CB1 receptor (M. Rinaldi-Carmona, submit- 
ted). These data together with the absence of blocking effect of 
the cannabinoid-induced B-cell activation by the specific CB1 
antagonist SR141716A 13 led us to assume that the enhancing 
activity observed on B-cells could be mediated through the 
peripheral-restricted CB2 receptor. Definitive information will 
depend on the availability of a CB2 specific antagonist or 
blocking antibodies. 
Whatever the subtype of CB receptor involved, we demon- 
strated that immunomodulation by cannabinoids is not limited 
to supression after exposure to very high concentrations of
ligands but that B-lymphocytes which expressed both type of 
receptors were sensitive to the stimulating effect of nanomolar 
concentrations of cannabinoids. This could have an as yet un- 
appreciated influence on human B-cell humoral activity and 
immune response in general as well. 
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